Skip to main content

The microbial contract biomanufacturing market is estimated to be worth USD 9.3 billion in 2030, predicts Roots Analysis

 

Benefits offered by microbial biomanufacturing, such as low production costs and faster development timelines, have led many innovators to adopt these platforms for next generation biologics, offering lucrative opportunities for CMOs / CDMOs

 

Roots Analysis is pleased to announce the publication of its recent study, titled, “Microbial Contract Biomanufacturing Market, 2020-2030.

 

The report features an extensive study of the current market landscape and future opportunities associated with the microbial contract biomanufacturing market. It features a detailed analysis of key drivers and trends related to this evolving domain. In addition to other elements, the study includes:

§  A detailed review of the current landscape of companies offering contract manufacturing services.

§  Elaborate profiles of key players that specialize in offering services for contract biomanufacturing.

§  A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.

§  An analysis of the partnerships and expansions that have been established in this domain, in the recent past.

§  A competitiveness analysis, highlighting key players engaged in microbial based contract manufacturing, featuring insightful pictorial summaries and representations.

§  A detailed proprietary 2×2 representation to assess the current market scenario

§  An analysis of the initiatives of big biopharma players engaged in this domain.

§  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)

§  Type of Product

§  API

§  FDF

 

§  Type of Biologic

§  Proteins

§  Enzymes

§  Growth Hormones

§  Antibody based Drugs

§  Others (plasmid DNA, probiotics, microbiome-based biologics)

 

§  Type of Microbial Expression System

§  Bacteria

§  Yeast

§  Others (Algae and fungi)

 

§  Scale of Operation

§  Commercial

§  Preclinical / Clinical

 

§  Type of End User

§  Small Companies

§  Mid-sized Companies

§  Large / Very Large Companies

 

§  Key Geographical Regions

§  North America

§  Europe

§  Asia Pacific

§  Middle East and North Africa

§  Latin America

To request a sample copy / brochure of this report, please visit this - https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market/request-sample.html

 

 

Key companies covered in the report

§  AGC Biologics

§  Aldevron

§  BioVectra

§  EirGenix

§  Etinpro

§  Eurogentec

§  Northway Biotechpharma

§  Ology Bioservices

§  Porton Biopharma

§  Stelis Biopharma

 

For additional details, please visit 

https://www.rootsanalysis.com/reports/microbial-contract-biomanufacturing-market.html or email sales@rootsanalysis.com

 

You may also be interested in the following titles:

1.     Drug Repurposing Service Providers Market, 2020 – 2030

2.     Antibody Discovery Services and Platforms Market (3rd Edition), 2020-2030

3.     Live Biotherapeutic Products and Microbiome Contract Manufacturing Market: Focus on Active Pharmaceutical Ingredients and Finished Dosage Forms, 2020 - 2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Information

Roots Analysis Private Limited

Gaurav Chaudhary

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

Facebook - https://www.facebook.com/RootsAnalysis

LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/

Twitter - https://twitter.com/RootsAnalysis

 

 

 

 

 

Labels:

Comments

Post a Comment

Popular posts from this blog

The gene therapy market is projected to be worth USD 14.6 billion in 2030, growing at a CAGR of 30%, over the next decade, claims Roots Analysis

  Roots Analysis has announced the addition of “ Gene Therapy Market (4th Edition), 2020-2030” report to its list of offerings.   Success of approved gene therapies has resulted in a surge in interest of biopharmaceutical developers in this rapidly evolving domain. Presently, the ability of gene therapies to treat diverse disease indications is considered among the most prominent drivers of this market. In addition, promising clinical results of pipeline candidates are anticipated to draw in more investments to support product development initiatives.   To order this 720+ page report, which features 220+ figures and 375+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/gene-therapies-market/268.html   Key Market Insights   Around 800 gene therapies are currently being developed across different stages Apart from 10 approved products, most of the aforementioned therapies (65%) are in the early stages of developmen...
Post a Comment
Read more

The synthetic lethality-based drugs and targets market is estimated to be worth USD 8 billion in 2030, predicts Roots Analysis

  Advances in molecular screening technology have enabled the identification of novel synthetic lethal gene combinations, enabling the development of lead candidates that leverage the aforementioned phenomenon to offer therapeutic benefit.   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Synthetic Lethality-based Drugs and Targets Market, 2019-2030: Focus on DNA Repair (including PARP Inhibitors) and Other Novel Cellular Pathways ”.   The   report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of such compact diagnostic devices, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the current market landscape, providing information on drug developer(s) phase of development, type of ...
Post a Comment
Read more

The “China Pharmaceutical Contract Manufacturing Services Market, 2020-2030” report features an extensive study of the current market landscape and future opportunities associated with the pharmaceutical contract manufacturing market in China.

  Key Inclusions §   A review of the current market landscape of companies offering pharmaceutical contract manufacturing services in China, along with information on year of establishment, company size, location of headquarters, type of product (active pharmaceutical ingredients (APIs), intermediates and finished dosage formulations (FDFs)), type of FDFs, type of packaging and number of manufacturing facilities. §   A detailed landscape of the pharmaceutical manufacturing facilities in China, including an analysis based on location of these facilities, highlighting key manufacturing hubs. §   A brief discussion of various guidelines laid down by regulatory authorities in China for the manufacturing of pharmaceuticals. It also provides information on various challenges, related to regulatory scrutiny, faced by pharmaceutical manufacturers in China. §   Elaborate profiles of key players that offer a diverse range of capabilities for the manufacturing of p...
Post a Comment
Read more